FILING ANALYSIS · FRIDAY, NOVEMBER 6
Moderna, Inc. MRNA — 8-K: Results of Operations and Financial Condition
positive
Moderna reported a 29% revenue growth in the third quarter and increased its full-year revenue growth outlook to 15%-25%, also improving its GAAP operating expense outlook and ending cash balance expectations, driven by the launch of updated COVID vaccines and expansion of its approved respiratory vaccine portfolio.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →